Herceptin | search
Click here to view Herceptin news from 60+ newspapers.
Bookmark or Share- Herceptin® (trastuzumab) Dosing in HER2+ Adjuvant Breast CancerHerceptin Dosing for Adjuvant Breast Cancer Patients. Administer according to one of the following doses and schedules for a total of 52 weeks of Herceptin therapy: During and following paclitaxel, docetaxel, or docetaxel/carboplatin:
- Potential Side Effects of HerceptinLearn about potential side effects when using Herceptin® (trastuzumab) as a HER2+ metastatic breast cancer treatment. Read the Important Safety Information (ISI) for Herceptin® (trastuzumab). See full safety & Boxed Warnings for more information.
- What to Expect During Treatment - herceptinWhat to expect with Herceptin® (trastuzumab), a treatment for HER2+ early breast cancer including monitoring potential side effects, heart monitoring and testing during treatment. See full safety & Boxed Warnings for more information.
- Herceptin Treatment ScheduleRead about the treatment schedule for Herceptin® (trastuzumab), a treatment for HER2+ early breast cancer. See Full Safety and Boxed Warnings for more information. For US Healthcare Professionals
- Metastatic Breast Cancer - herceptinLearn about the specific types of HER2+ cancers that Herceptin® (trastuzumab) treats and its history of treating 2.3 million people over 20 years. See full safety & Boxed Warnings for more information.
More
